The science of epigenetics received a boost on 29 July with the announcement by Celgene Corporation of plans to invest in HDAC inhibitors under development by Acetylon Pharmaceuticals Inc of the US, with an option to buy the company. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
